Skip to content

Vildagriptin versus metformin adding to the inadequate controled type 2 diabetes with multiple daily insulin injection (VMAT)

Vildagriptin versus metformin adding to the inadequate controled type 2 diabetes with multiple daily insulin injection (VMAT) - Vildagriptin versus metformin adding to the type 2 diabetes with multiple daily insulin injection (VMAT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024663
Enrollment
30
Registered
2016-11-01
Start date
2014-12-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Adding vildagriptin 100mg to the type 2 diabetes patients with multiple daily injection. Adding metformin 1500mg to the type 2 diabetes patients with multiple daily injection.

Sponsors

Toho University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Type 2 diabtes patients who had diagnosed 12 months ago. (2)Patients medicated basal-bolus therapy for more than 12 month (3) Adalts who are 20 years or older (4) Patients who can understand consent brief and other explanation documents having the ability of the agreement about participation in this examination

Exclusion criteria

Exclusion criteria: (1) Type 1 diabetes mellitus patients (2) Patients with severe liver disease (3) Patients with severe renal disease (4) Patients who had myocardial infarction within 3 months, or obvious heart failure case (5) Patients with severe pancreas disease (6) Patients having a cancer (7) Patients with hemoglobin (Hb) less than 11 g/dL (8) Patients that the number of the platelets is less than 100,000 /mm3 (9) Patients with high diabetic neuropathy (10) Patients having a proliferative retinopathy (11) Patients with a serious infectious disease or a serious injury (12) Patients with bowel disease or ileus factors (13) Chronic enteropathy patients with the digestion and absorption abnormality (14) Excessive common custom drinker (15) A pregnant woman or the woman who may be pregnant (16) Patients who was infected with hepatitis B virus or hepatitis C virus (17) In addition, the patient who judged inappropriate by an attendant physician

Design outcomes

Primary

MeasureTime frame
Daily glucose fluctuation (MAGE,SD)

Secondary

MeasureTime frame
incidence of hypoglycemia, change of HbA1c,Ratio of bolus inslin and basal insulin

Countries

Japan

Contacts

Public ContactHiroshi Uchino

Toho University School of Medicine Divsion of diabetes, metabolism and endocrinology

h.uchino@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026